Pfizer (PFE) Analysts Show Caution Amid 50% Stock Decline
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowCurrently, only 2 out of 29 analysts rate Pfizer (PFE) as strong buy, while over 60% suggest a cautious outlook with ratings of hold, underperform, or sell. The stock has declined more than 50% from its 2021 peak. Patent expirations for key drugs like Eliquis and Vyndaqel are expected to impact revenues significantly by 2028. Despite these challenges, Pfizer maintains a dividend yield of 6.6%, much higher than the market average of 1.1%. The company continues efforts in drug development, including acquiring a promising GLP-1 candidate after dropping its own.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Pfizer Inc. (PFE)
Pfizer is one of the world’s largest pharmaceutical companies, developing vaccines and medicines across many therapeutic areas.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier PFE news
- Innovent (HK:1801) Shares Rise 10% After $10.5 Billion Pfizer Deal
- Pfizer (PFE) Lacks Earnings Momentum According to Analyst Jim Cramer
- Pfizer (PFE) Stock Down Over 50% from 2021 High Amid Challenges
- Pfizer (PFE) Receives FDA Approval for Veppanu Breast Cancer Drug
- Bristol Myers (BMY) Q1 profits rise 4% with $11.49 billion revenue
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
